Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8228957 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 7 Pages |
Abstract
This small randomized trial indicates that ICT followed by CHART is feasible and well tolerated. Despite closing early because of poor accrual, and so failing to show clear evidence of a survival benefit for the additional chemotherapy, the results suggest that CHART, and ICT before CHART, remain important options for the treatment of inoperable NSCLC and deserve further study.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Matthew F.R.C.R., Matthew M.Sc., Ethan M.B.B.Chir., Stephen M.D., Cheryl B.Sc., Neal M.D., Richard Stephens, Mahesh D.Phil.,